Abstract
In this study, the investigators conducted an 8-week randomized placebo-controlled trial on the use of citalopram for the treatment of late-life anxiety disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF 3rd. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146–50.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Joshi, P., Tampi, R.R. (2022). Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results from an 8-Week Randomized, Placebo-Controlled Trial. In: Tampi, R.R., Tampi, D.J., Young, J.J., Balasubramaniam, M., Joshi, P. (eds) Essential Reviews in Geriatric Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-94960-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-94960-0_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-94959-4
Online ISBN: 978-3-030-94960-0
eBook Packages: MedicineMedicine (R0)